AU2018326721B2 - Compounds and compositions for IRE1 inhibition - Google Patents

Compounds and compositions for IRE1 inhibition Download PDF

Info

Publication number
AU2018326721B2
AU2018326721B2 AU2018326721A AU2018326721A AU2018326721B2 AU 2018326721 B2 AU2018326721 B2 AU 2018326721B2 AU 2018326721 A AU2018326721 A AU 2018326721A AU 2018326721 A AU2018326721 A AU 2018326721A AU 2018326721 B2 AU2018326721 B2 AU 2018326721B2
Authority
AU
Australia
Prior art keywords
amino
pyrazin
imidazo
naphthalen
cyclohex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018326721A
Other languages
English (en)
Other versions
AU2018326721A1 (en
Inventor
Bradley J. Backes
George Hynd
Richard M. Keenan
Jamie Knight
Dustin J. MALY
Scott A. OAKES
Feroz R. PAPA
Charles Reynolds
Jon Sutton
Ben Whittaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Optikira LLC
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Optikira LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD, Optikira LLC filed Critical University of California Berkeley
Publication of AU2018326721A1 publication Critical patent/AU2018326721A1/en
Application granted granted Critical
Publication of AU2018326721B2 publication Critical patent/AU2018326721B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2018326721A 2017-09-01 2018-08-31 Compounds and compositions for IRE1 inhibition Ceased AU2018326721B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553320P 2017-09-01 2017-09-01
US62/553,320 2017-09-01
PCT/US2018/049081 WO2019046711A2 (en) 2017-09-01 2018-08-31 COMPOUNDS AND COMPOSITIONS FOR INHIBITING IRE1

Publications (2)

Publication Number Publication Date
AU2018326721A1 AU2018326721A1 (en) 2020-03-12
AU2018326721B2 true AU2018326721B2 (en) 2022-12-01

Family

ID=65526075

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018326721A Ceased AU2018326721B2 (en) 2017-09-01 2018-08-31 Compounds and compositions for IRE1 inhibition

Country Status (13)

Country Link
US (1) US11649237B2 (enExample)
EP (1) EP3675858B1 (enExample)
JP (1) JP2020532589A (enExample)
KR (1) KR20200066301A (enExample)
CN (1) CN111526877B (enExample)
AU (1) AU2018326721B2 (enExample)
BR (1) BR112020004226A2 (enExample)
CA (1) CA3074139A1 (enExample)
IL (1) IL272845B2 (enExample)
MX (1) MX2020002322A (enExample)
SG (1) SG11202001609RA (enExample)
WO (1) WO2019046711A2 (enExample)
ZA (1) ZA202001320B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020059841A1 (ja) * 2018-09-21 2020-03-26 国立大学法人 長崎大学 プリオン病治療薬
CA3131386A1 (en) * 2019-02-27 2020-09-03 Richard Keenan Imidazolopyrazine compounds for ire1 inhibition
BR112021016974A2 (pt) * 2019-02-27 2021-11-30 Optikira Llc Compostos de pirazolopiridina para inibição de ire1
US20230331719A1 (en) * 2020-08-07 2023-10-19 Optikira, LLC Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same
EP4243815A4 (en) * 2020-11-13 2024-10-02 The Regents of the University of California IRE1ALPHA INHIBITORS AND USES THEREOF
JP2025504791A (ja) * 2022-01-07 2025-02-19 アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル ヒドロキシフェニル部分を含む化合物及びその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014052669A1 (en) * 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
EP2283020B8 (en) 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
WO2011047384A2 (en) * 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
CN103079558B (zh) 2010-04-05 2025-09-12 上海复星医药产业发展有限公司 IRE-1α抑制剂
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2017152117A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
WO2018102751A1 (en) 2016-12-02 2018-06-07 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014052669A1 (en) * 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1

Also Published As

Publication number Publication date
CN111526877A (zh) 2020-08-11
WO2019046711A2 (en) 2019-03-07
IL272845B1 (en) 2023-08-01
RU2020112425A3 (enExample) 2022-03-31
BR112020004226A2 (pt) 2020-11-17
EP3675858A4 (en) 2021-03-17
IL272845A (en) 2020-04-30
EP3675858A2 (en) 2020-07-08
MX2020002322A (es) 2020-10-05
US11649237B2 (en) 2023-05-16
EP3675858B1 (en) 2023-04-26
SG11202001609RA (en) 2020-03-30
ZA202001320B (en) 2023-10-25
US20200354367A1 (en) 2020-11-12
IL272845B2 (en) 2023-12-01
KR20200066301A (ko) 2020-06-09
AU2018326721A1 (en) 2020-03-12
RU2020112425A (ru) 2021-10-04
CN111526877B (zh) 2023-08-25
JP2020532589A (ja) 2020-11-12
WO2019046711A3 (en) 2020-04-02
CA3074139A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
AU2020341681B2 (en) RIP1 inhibitory compounds and methods for making and using the same
EP3675858B1 (en) Imidazo[1,5-a]pyrazine compounds and compositions for ire1 inhibition
EP3781156A1 (en) Spirocyclic compounds
ES2893289T3 (es) Inhibidores de glucosidasa
AU2018420231B2 (en) Phenyl triazole MLL1-WDR5 protein-protein interaction inhibitor
US9096614B2 (en) Therapeutically active thiazolo-pyrimidine derivatives
CA3108809C (en) Heteroaromatic compounds, pharmaceutical compositions and uses thereof
WO2014165090A1 (en) Compounds for the treatment of tuberculosis
US20190263828A1 (en) Heteroaromatic compounds as vanin inhibitors
US9951061B2 (en) CaMKII inhibitors and uses thereof
CA3005918A1 (en) Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
AU2013282953A1 (en) 2-aminopyrazine derivatives as CSF-1 R kinase inhibitors
CA3106513A1 (en) Heteroaromatic compounds as vanin inhibitors
JP2019509272A (ja) 脊髄性筋萎縮症の治療のための併用療法
US20220048889A1 (en) Heteroaromatic compounds as vanin inhibitors
WO2017073743A1 (ja) 三環性化合物
US20220370431A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
EP4011880A1 (en) Jak kinase inhibitor and use thereof
CN103435562B (zh) 6-取代苯并二氮卓-2,4-二酮类化合物及其用途
WO2017021216A1 (en) Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent.
RU2795572C2 (ru) Соединения и композиции для ингибирования ire1
US20220194945A1 (en) Imidazolopyridine Compounds For IRE1 Inhibition
US20260055100A1 (en) Indane and coumaran derivatives as fast skeletal muscle myosin inhibitors
CN122071475A (zh) 三元稠环类衍生物及其医药用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired